Faculty of Pharmaceutical Science, Mata Gujri College of Pharmacy, Mata
Gujri University,Kishanganj, Bihar, 855107, India

Corresponding author email: gautamjagjot.mgcop@gmail.com

Article Publishing History

INTRODUCTION

The DTA describes DT_X is software that provides proven treatments to help patients prevent, manage, or treat health issues. People use them independently or in combination with drugs, technology, or alternative treatments to improve patient care and health outcomes [1]. The DT_x as “evidence-based, clinically evaluated software designed to treat, manage, and prevent a wide array of disease as well disorder [2, 3].” Digital health encompasses technology that facilitates the storage and access of patient health information, including telemedicine consultations and software designed to streamline clinical treatment [4,5]. Digital Health Innovation are not mandated to demonstrate clinical effectiveness and hence do not need clearance from regulatory authorities [5].

Digital medicine encompasses technology that enables the diagnosis of specific disease states and customises healthy choices for patients [6,7]. The FDA acknowledged the significance of digital health for patient well-being and established the Digital Health Centre of Excellence in 2020 to facilitate the regulatory process in alignment with its safety protocols [8]. Digital therapeutics (DTx) includes the use of technology to provide therapeutic comfort and care to patients beyond conventional medical approaches. Their potential to complement or replace standard-of-care treatments continues to grow, especially in the management of chronic diseases and mental health conditions [9-13] .

History: In 1995, Dr. Joseph Kvedar from Boston, USA, initiated a study to investigate how technology could be leveraged to deliver care beyond traditional hospital or clinical settings, introducing the “one-to-many model of care 6,7]. Literature evidence illustrating the use of digital goods to achieve improved health outcomes goes back to 2000 [8,9]. The name “DTx” has been formally used since 2012 [10, 11]. Currently, the prevalence of electronic patients is increasing. They are more actively engaged and seek to be involved in informed decisions regarding their treatment options. These anticipate knowledgeable responses to their enquiries on medical and health technologies from their doctors [12, 13]. Individuals who possess the tools, resources, and confidence to take control of their health and make informed healthcare decisions are referred to as e-patients. [14, 15].

 Characteristics of digital therapeutics: Both traditional medicine and digital therapeutics (DTx) need to be proven effective for specific diseases and require a prescription, but they are very different in many areas, such as how they are developed, tested, approved, distributed, used in clinics, and managed after they are on the market[16,17]. Digital therapeutics need much lower development costs in comparison to medicines, and the development timeline is almost halved [18,19]. Furthermore, as they are not used, there is no need for manufacturing facilities or material expenses for supplementary manufacture after the first invention [20,21].

In contrast to pharmaceuticals, which are distributed to patients via manufacturers, wholesalers, retailers, and medical suppliers, digital therapeutics (DTx) streamline the delivery process directly from developers and platform providers to patients [22,23]. DTx can secure marketing approval through optional piloting and pivotal clinical trials via the medical device regulatory pathway in most countries. DTx relies on the effectiveness of such modifications over time [24, 25]. Pharmaceuticals are categorised as either over-the-counter or prescription drugs based on the need for a prescription [26]. Digital therapeutics (DTx) are categorised as prescription digital therapeutics (PDTx) if they need a prescription [27]. Furthermore, DTx may enhance their functionality (efficacy) or eliminate it via upgrades. Digital therapeutics (DTx) may be influenced by demographic characteristics as well as social and cognitive capabilities [28].

Regulatory Framework for Digital Therapeutics under the U.S. FDA

U.S. FDA Guidelines and Initiatives for DTX: The U.S. FDA categorizes digital therapeutics under the broader classification of mobile medical applications (MMAs) [31]. Instances of MMAs subject to this enforcement discretion encompass: a. Applications designed to help patients manage and track their personal health records and data. b. Digital tools that provide users with easy access to reliable information about medical conditions and available treatment options. c. Digital applications that support patients in independently managing their own health issues or conditions (such as wellness apps) without providing direct therapeutic intervention [32].

The U.S. FDA’s initiative, outlined in its Digital Health Innovation Action Plan, aims to ensure access to high-quality, safe, and effective digital health solutions for all patients. Due to recent regulatory developments, the FDA has started the overhaul of its review process for digital health products [33]. The action plan delineates the methods for assessing digital health goods according to corporate attributes rather than the effectiveness of individual items [34, 35]. This assessment is novel and seeks to enhance the evaluation of the repetitive aspects of software development, which may advance more rapidly and cost-effectively than traditional prototype methods [36, 37]. As DTx products await clearance, authorities are struggling to manage the volume and verify the absence of misleading claims [38].

The DTA industry association anticipates that new member businesses will adopt specific principles and best practices to instill in users confidence about substantial proof and compliance with regulatory approvals. These compliance standards involve publishing data in peer-reviewed journals, demonstrating validated results from clinical trials, and ensuring strong safeguards for data privacy and security [39, 40]. The DTA advocates that adherence to such criteria is vital for setting DTx apart from wellness apps or general digital health tools [41]. This disciplined approach is crucial in ensuring that DTx are integrated into mainstream healthcare as trusted, regulated therapeutic options [42, 43].

Emerging Landscape of Digital Therapeutics in India: Indian pharmaceutical firms are currently reshaping their business models, innovating product development strategies, and adjusting their offerings to align with evolving healthcare trends and technological progress. [44]. Digital therapeutics (DTx) services are projected to reduce drug development and manufacturing costs while offering value to insurers through personalised treatment solutions tailored to patient-specific needs [45]. Although DTx adoption remains limited in India, there is a growing interest among startups and established players who are preparing to invest in and enter the DTx space [46]. This evolving landscape suggests the potential for significant growth, supported by increasing digitisation, rising patient awareness, and supportive regulatory discussions [47, 48].

Future in DTX: Digital therapeutics firms have mostly concentrated on behavioural and chronic disorders; however, several manufacturers have started to expand their product offerings to include acute ailments. Click Therapeutics is developing a digital therapeutic for acute coronary syndrome [49, 50]. The FDA in the United States, along with other regulatory bodies globally, has been making significant efforts to refine their regulatory frameworks to facilitate the creation, assessment, and, where appropriate, approval of innovative digital therapies “at digital speed”[51,52]. The clinical evaluation of digital therapies presents distinct problems and potential.

The randomised, double-blind, placebo- and active-controlled trial design is the benchmark for producing clinical evidence [53, 54]. Digital data are more easily processed than non-digital data, allowing for real-time design modifications that enhance trial efficiency [55]. Several creative designs grounded in behaviour change theory have been created [56, 57]. The FDA provides guidance on particular aspects of medical device clinical trials, which can prove useful in evaluating digital therapeutics in this setting. [57,58]. The global deployment of DTx is expected to greatly benefit regions like the Global South, where limited healthcare personnel relative to patient populations may contribute to overburdened and under-resourced healthcare systems. [59].

As part of follow-up care, digital therapeutics have delivered essential rehabilitation exercises and facilitated virtual consultations to support stroke patients in India, where the healthcare system struggles to accommodate the high patient load[60]. Such implementations show the capacity of DTx to provide scalable, evidence-based interventions where traditional resources are constrained [61]. As innovation continues, these technologies are expected to play an increasingly central role in global healthcare delivery [62].

CONCLUSION

Digital therapeutics has transitioned from theoretical instruments to vital elements of contemporary healthcare. As innovation propels more advanced and tailored therapies, regulatory agencies must adapt to guarantee safety, effectiveness, and equal access. The success of digital therapeutics (DTx) hinges on the joint endeavours of technologists, physicians, regulators, and patients to establish an environment that fosters innovation while upholding stringent clinical standards. By connecting technological innovation with medical practice, DTx has the ability to transform healthcare delivery into a more proactive, data-driven, and patient-centered model. The future of medicine will ultimately depend on the efficacy of integrating digital technologies into routine clinical practice.

REFERENCES

1. DTA. Digital therapeutics alliance. [homepage on the Internet]; 2017. Available from: https://www.dtxalliance. org/. [Cited 2020 Jan 09].
2. Digital Therapeutics Alliance. Digital Therapeutics: Definition and Core Principles [Internet]. Washington (DC): DTA; [cited 2025 May 27]. Available from: https://dtxalliance.org
3. Mesko B, Drobni Z, Bényei É, Gergely B, Győrffy Z. Digital health is a cultural transformation of traditional healthcare. mHealth. 2017;3:38.
4. Understanding DTx. Accessed January 13, 2023. https://dtxalliance. org/understanding-dtx/
5. Meskó B, Topol EJ. The role of wearable technologies in managing chronic diseases. Nat Biotechnol. 2014;32(9):938–40.
6. Fleming GA, Petrie JR, Bergenstal RM, Holl RW, Peters AL, Heinemann L. Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care. 2019;43(1):250-260
7. Topol EJ. A decade of digital medicine innovation. Lancet. 2019;394(10205):484.
8. U.S. Food and Drug Administration. Digital Health Center of Excellence [Internet]. Silver Spring (MD): FDA; 2020 [cited 2025 May 27]. Available from: https://www.fda.gov/medical-devices/digital-health-center-excellence
9. Gerke S, Stern AD, Minssen T. Germany’s digital health reforms in the COVID-19 era: Lessons and opportunities for other countries. NPJ Digit Med. 2020;3:94.
10. Marra C, Chen JL, Coravos A, Stern AD. Quantifying the use of connected digital products in clinical research. NPJ Digit Med. 2020;3:50.
11. Kvedar JC, Fogel AL. Digital medicine’s march on chronic disease. Nat Biotechnol. 2016;34(3):239–46.
12. FDA. FDA launches the digital health center of excellence. 2020. FDA.gov
13. Dang A, Arora D, Rane P. Role of digital therapeutics and the changing future of healthcare. J Fam Med Prim Care. 2020;9(5):2207-2213
14. Makin S. The emerging world of digital therapeutics. Nature 2019;573:S106‑9.
15. Kvedar J, Coye MJ, Everett W. Connected health: a review of technologies and strategies to improve patient care with telemedicine and telehealth. Health Aff (Millwood). 2014;33(2):194–9.
16. Capobianco E. On Digital Therapeutics. Front Digit Humanit 2015;2:6.
17. Pagliari C, Sloan D, Gregor P, Sullivan F, Detmer D, Kahan JP, et al. What is eHealth (4): A scoping exercise to map the field. J Med Internet Res. 2005;7(1):e9.
18. Digital Therapeutics Alliance. About digital therapeutics [Internet]. Washington (DC): Digital Therapeutics Alliance; c2012 [cited 2025 May 27]. Available from: https://dtxalliance.org/about-dtx
19. United States Patent and Trademark Office. [homepage on the internet]. 2012. Available from: http://tsdr.uspto.gov/ documentviewer?caseId=sn85765357&docId=FTK2012110 1070417#docIndex=4&page=. [Cited 2020 Jan 09].
20. Moar J. Digital therapeutics and wellness [homepage on the Internet]. Juniper Research. Available from: https://www. juniperresearch.com/researchstore/innovation‑disruption/ digital‑therapeutics‑wellness. [Updated 2019 May 15; Cited 2020 Jan 09].
21. Fox S, Duggan M. Health online 2013. Pew Research Center [Internet]. 2013 [cited 2025 May 27]. Available from: https://www.pewresearch.org/internet/2013/01/15/health-online-2013/
22. Society for Participatory Medicine. [homepage on the internet]. Available from: https://participatorymedicine. org/epatients/about‑e‑patientsnet
23. Ferguson T. E-patients: how they can help us heal healthcare. e-Patients.net [Internet]. 2007 [cited 2025 May 27]. Available from: https://e-patients.net/e-Patient_White_Paper.pdf
24. Gerke S, Minssen T, Cohen G. Ethical and legal challenges of digital health. Lancet Digit Health. 2020;2(8):e425–7.
25. Van Norman, G. A. Drugs, devices, and the FDA: Part 2: An Overview of Approval Processes: FDA approval of medical devices.JACC Basic Transl. Sci. 1, 277–287 (2016).
26. EUROPEAN MEDICINES AGENCY. ICH Guideline E8 (R1) on General Considerations for Clinical Studies https://www.ema.europa.eu/en/ich-e8-general-considerationsclinical-studies (2022).
27. Muoio D. Digital therapeutics timeline: Milestones in the growing field of software-based treatments. MobiHealthNews [Internet]. 2020 [cited 2025 May 27]. Available from: https://www.mobihealthnews.com
28. Dinesen B, Nonnecke B, Lindeman D, Toft E, Kidholm K, Jethwani K, et al. Personalized telehealth in the future: a global research agenda. J Med Internet Res. 2016;18(3):e53.
29. International Organization for Standardization. ISO 14155:2020—Clinical Investigation of Medical Devices for Human Subjects—Good Clinical Practice https:// www.iso.org/obp/ui/#iso:std:iso:14155:ed-3:v1:en (2020).
30. Huh, K. Y., Oh, J., Lee, S. & Yu, K. S. Clinical evaluation of digital therapeutics: present and future. Health. Inf. Res. 28, 188–197 (2022).
31. Dinesen B, Nonnecke B, Lindeman D, Toft E, Kidholm K, Jethwani K, et al. Personalized telehealth in the future: a global research agenda. J Med Internet Res. 2016;18(3):e53.
32. Park, K. M., Lee, S. & Lee, E. Can digital therapeutics open a new era of sleep medicine. Chronobiol. Med. 3, 142–148 (2021).
33. U.S. Food and Drug Administration. Digital Health Software Precertification (Pre-Cert) Program [Internet]. 2020 [cited 2025 May 27]. Available from: https://www.fda.gov
34. Martinez-Millana A, Jarones E, Fernandez-Llatas C, Traver V. Monitoring and helping patients using pervasive and wearable technologies. J Biomed Inform. 2018;79:76–97.
35. Digital Therapeutics Alliance. Understanding prescription digital therapeutics [Internet]. 2020 [cited 2025 May 27]. Available from: https://dtxalliance.org
36. Digital Therapeutics Alliance. Understanding prescription digital therapeutics [Internet]. 2020 [cited 2025 May 27]. Available from: https://dtxalliance.org
37. Sverdlov O, van Dam J, Hannesdottir K, Thornton‑Wells T. Digital therapeutics: An integral component of digital innovation in drug development. Clin Pharmacol Ther 2018;104:72‑80.
38. Examples of software functions for which the FDA will exercise enforcement discretion [monograph on the internet] USFDA. Available from: https://www.fda.gov/ medical‑devices/device‑software‑functions‑includingmobile‑medical‑applications/examples‑software‑function s‑which‑fda‑will-exercise‑enforcement‑discretion. [Updated 2019 Sept 26; Cited 2020 Jan 09].
39. U.S. Food and Drug Administration. Mobile Medical Applications Guidance for Industry and Food and Drug Administration Staff. Silver Spring (MD): FDA; 2015 [cited 2025 May 27]. Available from: https://www.fda.gov
40. U.S. Food and Drug Administration. Policy for Device Software Functions and Mobile Medical Applications. 2022 [cited 2025 May 27]. Available from: https://www.fda.gov/media/80958/download
41. U.S. Food and Drug Administration. Digital Health Innovation Action Plan. 2017 [cited 2025 May 27]. Available from: https://www.fda.gov/media/106331/download
42. 34.Digital health innovation action plan. [monograph on the internet] USFDA centre for devices and radiological health, Digital health program. Available from: https://www.fda. gov/media/106331/download. [Cited 2020 Jan 09].
43. Patel BN, Rosenfeld PJ, Ramaswamy RS. FDA’s evolving regulatory approach for digital health technologies. JAMA. 2021;325(6):523–4
44. Martin M. The dawn of digital therapeutics [monograph on the Internet]. Platypus. Available from: http://blog.castac. org/2019/04/the‑dawn‑of‑digital‑therapeutics/. [Updated 2019 Apr 16; Cited 2020 Jan 09].
45. Shuren J, Patel B. FDA regulation of mobile medical apps and software-based devices. N Engl J Med. 2018;378(6):510–2.
46. Tarricone R, Cucciniello M, Armeni P. Digital therapeutics: a lighthouse for the healthcare system. Health Econ. 2021;30(8):1750–3.
47. Makin S. The emerging world of digital therapeutics. Nature 2019;573:S106‑9.
48. Gerke S, Stern AD, Minssen T. Germany’s digital health reforms in the COVID-19 era: Lessons and opportunities for other countries. NPJ Digit Med. 2020;3:94.
49. Gerke S, Stern AD, Minssen T. Germany’s digital health reforms in the COVID-19 era: Lessons and opportunities for other countries. NPJ Digit Med. 2020;3:94.
50. Mesko B. The guide to the future of medicine: Technology AND the human touch. Las Vegas: Webicina; 2014.
51. Blease C, Kaptchuk TJ, Bernstein MH, Mandl KD, Halamka JD, DesRoches CM. Artificial intelligence and the future of primary care: Exploratory qualitative study of UK general practitioners’ views. J Med Internet Res. 2019;21(3):e12802.
52. EY India. Pulse of the Industry: India Life Sciences Landscape 2022. Ernst & Young Global Limited; 2022 [cited 2025 May 27]. Available from: https://www.ey.com/en_in
53. FICCI-EY. Leapfrogging to a Digital Healthcare Ecosystem: Reimagining Healthcare for Every Indian. Federation of Indian Chambers of Commerce & Industry; 2021 [cited 2025 May 27]. Available from: https://ficci.in
54. MobiHealthNews. India’s growing digital health space draws pharma and startups. MobiHealthNews [Internet]. 2023 [cited 2025 May 27]. Available from: https://www.mobihealthnews.com
55. ET HealthWorld. Digital therapeutics: The next frontier in India’s healthcare innovation. Economic Times HealthWorld [Internet]. 2022 [cited 2025 May 27]. Available from: https://health.economictimes.indiatimes.com
56. KYT Adhere. Digital Therapeutic Platform Optimizing Patient Engagement And Treatment Adherence. Available from: https://kyt.ai/. [Last accessed on 2020 Apr 06
57. Click Therapeutics. https://www.clicktherapeutics.com/products/ (2020).
58. ET HealthWorld. Digital therapeutics: The next frontier in India’s healthcare innovation. Economic Times HealthWorld [Internet]. 2022 [cited 2025 May 27]. Available from: https://health.economictimes.indiatimes.com
59. U.S. Food and Drug Administration. Digital Health
60. U.S. Food and Drug Administration. Fostering Digital Health Innovation: FDA’s Digital Health Innovation Action Plan [Internet]. 2021 [cited 2025 May 27]. Available from: https://www.fda.gov
61. Hariton E, Locascio JJ. Randomised controlled trials—the gold standard for effectiveness research. BJOG. 2018;125(13):1716.
62. European Medicines Agency. ICH E9: Statistical Principles for Clinical Trials. (5 February 1998
63. Marra C, Chen JL, Coravos A, Stern AD. Quantifying the use of connected digital products in clinical research. NPJ Digit Med. 2020;3:50.
64. Yardley L, Morrison L, Bradbury K, Muller I. The person-based approach to intervention development: application to digital health-related behaviour change interventions. J Med Internet Res. 2015;17(1):e30.
65. Collins, L.M., Murphy, S.A. & Strecher, V. The Multiphase Optimization Strategy (MOST) and the Sequential Multiple Assignment Randomized Trial (SMART): new methods for more potent eHealth interventions. Am. J. Prevent. Med. 32, S112–S118 (2007).
66. U.S. Food and Drug Administration. Design Considerations for Pivotal Clinical Investigations for Medical Devices: Guidance for Industry and FDA Staff [Internet]. 2013 [cited 2025 May 27]. Available from: https://www.fda.gov/media/87634/download
67. World Health Organization. The Global Health Observatory: Health Workforce Statistics [Internet]. 2022 [cited 2025 May 27]. Available from: https://www.who.int/data/gho
68. Sharma R, Singh A, Raj S, Goyal M. Digital physiotherapy interventions for post-stroke rehabilitation in rural India: a pilot study. Int J Telerehabil. 2021;13(2):55–61.
69. Kvedar JC, Fogel AL, Elenko E, Zohar D. Digital medicine’s march on chronic disease. Nat Biotechnol. 2016;34(3):239–46.
70. Mesko B, Drobni Z, Bényei É, Gergely B, Győrffy Z. Digital health is a cultural transformation of traditional healthcare. mHealth. 2017;3:38.